Inflammation and depression · CRP

Inflammation and Depression: Identifying the Inflamed Subgroup

Inflammation is linked to depression in a subgroup, not in everyone: a meta-analysis of 30 studies found CRP above 3 mg/L in 27 percent of patients with depression. The treatment signal sits where baseline CRP is high, so identifying that subgroup starts with measurement.

Anti-inflammatory trials in depression fail on average and succeed in the patients whose markers run high. That makes baseline measurement a clinical decision rather than an academic one.

The link between inflammation and depression is real, and it is not universal. Treated as a population average it looks weak; treated as a subgroup question it becomes a screening problem primary care is well placed to solve. The case is set out in Your Anxiety Is a Fire in Your Gut, the video accompanying the first clinical chapter of The Angry Gut, which frames the gut as the first brain and the organ in the skull as the second.

Measura [Cardiometabolic and Autonomic Health Analysis] supplies measurements to that workup. Diagnosis and management remain with the treating physician.

Can inflammation cause depression?

Endotoxin challenge in healthy volunteers produces depressed mood under randomized, placebo-controlled conditions, and in younger women the rise in interleukin-6 tracked the rise in depressed mood. The clinical analogue is interferon therapy for hepatitis C: across 26 prospective studies, the cumulative incidence of induced major depression was 0.25 at 24 weeks and 0.28 at 48. A prior depressive episode (OR 3.96) and higher baseline interleukin-6 predicted it.

Susceptibility varies more than the cytokine response does. In one hundred and fifteen healthy adults challenged with endotoxin, baseline perceived stress, social sensitivity and existing anxiety or depressive symptoms predicted mood decline, yet none of them related to the magnitude of cytokine increases, and differential AP-1 and NF-kB activation was already visible at thirty minutes. The inflammatory stimulus is common. The vulnerability is individual, and it is partly social.

How common is inflamed depression, and who responds to treatment?

A meta-analysis of 30 studies found CRP above 3 mg/L in 27 percent of patients with depression, with an odds ratio of 1.46 against controls, and above 1 mg/L in 58 percent. The inflamed fraction was not explained by sample source, antidepressant treatment, age, BMI or ethnicity.

Infliximab in treatment-resistant depression showed no overall effect but a significant interaction with baseline CRP. Above 5 mg/L, 8 of 13 patients responded against 3 of 9 on placebo, numbers too small to stand alone. Pooled across anti-inflammatory agents added to antidepressants, the effect reached SMD −0.64, from trials that all carried high risk of bias. The signal sits where the markers are high, which makes baseline measurement the decision point.

The strongest counterargument

Mendelian randomization in 68,769 Norwegian adults found no clear causal effect of genetically predicted CRP on depressive symptoms, and a UK Biobank analysis of the interleukin-6 receptor produced an odds ratio of 1.023. These designs estimate lifelong genetic set-points against questionnaire outcomes in general populations. They do not model inflammation acquired through adiposity, diet, barrier failure or repeated antibiotic courses, and none was conducted in metabolically ill, high-CRP patients. They argue against inflammation as the engine of depression population-wide, which is not the claim, and they are silent on the inflamed subgroup.

Where the fire is lit: the first brain

Gut-derived serotonin, roughly 90 to 95 percent of the body’s total, does not cross the blood-brain barrier. Dr. Padda describes having taught patients the opposite for years before the pharmacology corrected him. The routes that matter are vagal afferent signaling and cytokine induction of indoleamine 2,3-dioxygenase, which shunts tryptophan into the kynurenine pathway and leaves less for central synthesis.

Barrier proxies point the same way. Serum IgM and IgA against gram-negative lipopolysaccharide separated patients with major depression from controls with an area under the ROC curve of 90.1 percent. In married couples, hostile interaction tracked lipopolysaccharide-binding protein, and 79 percent of the highest quartile had mean daytime CRP above 3, against 21 percent of the lowest. Stool microbiome signatures are not a usable screen: across 59 case-control studies the shifted taxa were shared between disorders. Measura does not perform stool, breath or microbiome testing.

Inflammation and depression: who to measure and what a finding changes

• Depression or anxiety with metabolic features such as central adiposity or elevated fasting insulin.
• Treatment-resistant or partially responsive depression, particularly with coexisting bowel symptoms.
• Repeated antibiotic exposure or heavy polypharmacy; in vitro, 24 percent of drugs with human targets inhibited at least one gut bacterial strain.
• Positive depression screening at an annual wellness visit with no inflammatory or metabolic markers on file.

A practical measurement set: laboratory panels with CRP and fasting insulin selected by the ordering physician, repeating any elevated CRP because infection, injury and strenuous exercise raise it; bioimpedance body composition to quantify the adipose compartment; and heart rate variability as a resting autonomic index. A confirmed elevated CRP with metabolic findings moves management toward the terrain the book calls metaflammation, running alongside existing psychiatric care. It is not a basis for altering an antidepressant, which remains with the prescriber.

Pairing with cognition, and what intervention evidence supports

In older adults, mood, inflammatory status and cognition are usually raised at the same visits. A structured cognitive assessment recorded alongside the inflammatory markers establishes a baseline for later comparison, in line with the cognitive assessment and fall prevention protocol.

On the intervention side, dietary change carries the strongest data. SMILES randomized adults with major depression to dietary or social support and found a 7.1-point MADRS difference, an effect size of −1.16, remission of 32.3 against 8.0 percent and a number needed to treat of 4.1. Pooled dietary trials look smaller (g = 0.162), but 15 of 16 of them enrolled people without clinical depression. Probiotic effects shrink by nearly a third once high-bias trials are excluded.

Workflow and documentation

Specialty separation is the structural driver: mood, bowel and metabolism are managed in separate clinics, and nobody owns the connection. A standing order tying positive depression screening to CRP, fasting insulin and body composition turns the subgroup question into routine practice. Discrete results in the chart support HEDIS and value-based care documentation and annual wellness visit care plans, and let a repeat CRP be trended rather than rediscovered.

Full effect sizes, confidence intervals, and the transplant and vagus stimulation trials are compiled in the Chapter 1 Deep Dive for The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes. The preceding physician discussion covers autonomic function testing when symptoms begin in the gut. Depression that has lifted still leaves a cognitive risk worth tracking, addressed in remitted depression and cognitive decline.

Frequently asked questions

References

• Udina, M., Castellví, P., Moreno-España, J., Navinés, R., Valdés, M., Forns, X., Langohr, K., Solà, R., Vieta, E., & Martín-Santos, R. (2012). Interferon-induced depression in chronic hepatitis C: A systematic review and meta-analysis. The Journal of Clinical Psychiatry, 73(8), 1128–1138. https://doi.org/10.4088/JCP.12r07694
• Irwin, M. R., Cole, S., Olmstead, R., Breen, E. C., Cho, J. J., Moieni, M., & Eisenberger, N. I. (2019). Moderators for depressed mood and systemic and transcriptional inflammatory responses: A randomized controlled trial of endotoxin. Neuropsychopharmacology, 44(3), 635–641. https://doi.org/10.1038/s41386-018-0259-6
• Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B., & Khandaker, G. M. (2019). Prevalence of low-grade inflammation in depression: A systematic review and meta-analysis of CRP levels. Psychological Medicine, 49(12), 1958–1970. https://doi.org/10.1017/S0033291719001454
• Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry, 70(1), 31–41. https://doi.org/10.1001/2013.jamapsychiatry.4
• Köhler-Forsberg, O., N Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., & Benros, M. E. (2019). Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: Meta-analysis of clinical trials. Acta Psychiatrica Scandinavica, 139(5), 404–419. https://doi.org/10.1111/acps.13016
• Bekkevold, O.-J., Damås, J. K., Brumpton, B. M., & Åsvold, B. O. (2023). The causal role of C-reactive protein and interleukin-6 on anxiety and depression symptoms and life satisfaction: Mendelian randomisation analyses in the HUNT study. Psychological Medicine, 53(16), 7561–7568. https://doi.org/10.1017/S0033291723001290
• Kelly, K. M., Smith, J. A., & Mezuk, B. (2021). Depression and interleukin-6 signaling: A Mendelian randomization study. Brain, Behavior, and Immunity, 95, 106–114. https://doi.org/10.1016/j.bbi.2021.02.019
• Maes, M., Kubera, M., & Leunis, J.-C. (2008). The gut-brain barrier in major depression: Intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinology Letters, 29(1), 117–124. https://pubmed.ncbi.nlm.nih.gov/18283240/
• Jacka, F. N., O’Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., Castle, D., Dash, S., Mihalopoulos, C., Chatterton, M. L., Brazionis, L., Dean, O. M., Hodge, A. M., & Berk, M. (2017). A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’ trial). BMC Medicine, 15(1), 23. https://doi.org/10.1186/s12916-017-0791-y
• Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E. E., Brochado, A. R., Fernandez, K. C., Dose, H., Mori, H., Patil, K. R., Bork, P., & Typas, A. (2018). Extensive impact of non-antibiotic drugs on human gut bacteria. Nature, 555(7698), 623–628. https://doi.org/10.1038/nature25979

Related reading

• Autonomic Function Testing When Symptoms Begin in the Gut
• Deprescribing Starts With a Baseline, Not a Drug List
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.